Michael Russell Bishop
Professor of Medicine
Also affiliated: University of Nebraska at Omaha (1997); Universitat Autònoma de Barcelona (2021); National Institutes of Health (2001–2012); University of Minnesota (2002); Nebraska Medical Center (1994–2000); National Marrow Donor Program (2002–2005); University College London Hospitals NHS Foundation Trust (2024); The University of Texas MD Anderson Cancer Center (2008–2009); Cancer Research Institute (2005); Loyola University Chicago (1991); University of Washington (2002); Peking University (2013); Medical College of Wisconsin (1998–2012); University Hospitals Bristol NHS Foundation Trust (2024); Cancer Institute (WIA) (2009); San Diego Miramar College (2020); Newcastle upon Tyne Hospitals NHS Foundation Trust (2024); California Miramar University (2020); University of Illinois Chicago (2019–2025); University of Chicago (2013–2026); University of Chicago Medical Center (2013–2025); Office of the Director (2001); Northwestern University (2023); Palmetto Hematology Oncology (2019–2020); Peking University People's Hospital (2013); Cancer Research Center (2015); UPMC Hillman Cancer Center (2005); National Cancer Institute (2013); National Cancer Institute (2000–2012); Center for Cancer Research (2004–2012); University College London (2024); University of Nebraska Medical Center (1994–2000); University of Pennsylvania (2002–2005)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Michael Russell Bishop's research focuses on hematologic malignancies and stem cell transplantation, particularly in the context of immunotherapy and managing treatment-related adverse events. He has investigated outcomes for patients undergoing allogeneic hematopoietic cell transplantation, including the comparison of myeloablative versus reduced-intensity preparative regimens for acute myeloid leukemia and myelodysplastic syndromes. His work also extends to geriatric assessment in older adult transplant recipients to predict survival.
Dr. Bishop has been involved in studies evaluating novel therapeutic approaches, such as CAR-T cell therapy for relapsed or refractory adult B-cell acute lymphoblastic leukemia and aggressive B-cell lymphoma. He has also contributed to guidelines for managing immune effector cell-related adverse events. His research interests include the long-term health outcomes for survivors of childhood cancer, as well as future directions in the treatment of osteosarcoma.
Metrics
- h-index: 39
- Publications: 287
- Citations: 7,072
Positions
-
Professor of Medicine 2012–presentUniversity of Chicago Medicine ORCID
-
Professor of Medicine publications 2026University of Arkansas for Medical Sciences Institutional directory
Selected Publications
-
Polycythemia vera as a cause of systemic hypertension (2026)
Collaboration Network
Top Collaborators
- Polycythemia vera as a cause of systemic hypertension
- Polycythemia vera as a cause of systemic hypertension
Similar Researchers
Based on overlapping research topics